Radiation-induced gastrointestinal syndrome is a major complication and limiting factor for radiotherapy. Tumor suppressor p53 has a protective role in radiation-induced gastrointestinal toxicity.

The simplest explanation of cancer is that, for any reason, a cell in our body ignores its biological program and gets loose, multiplying itself again and again, creating a tumor. This has a lot to do ...

p53, which is encoded by the most frequently mutated gene in cancer, TP53, is an attractive target for novel cancer therapies. Despite major challenges associated with this approach, several compounds ...

The p53 tumor suppressor protein is encoded by TP53, the most frequently mutated gene in cancer. A review article published in Nature Reviews Clinical Oncology by Professor Klas G Wiman and colleagues ...

The tumor suppressor protein p53 has been dubbed the "guardian of the genome" because it protects the DNA from stress or long-term damage by regulating the expression of numerous genes involved DNA ...

Can networks of genes be stimulated using resonance? Researchers at the Niels Bohr Institute are investigating whether the protein p53, which activates a range of different genes, can be induced to ...

The tumor suppressor protein p53 plays a critical role in preventing cancer by regulating cell cycle, apoptosis, and genomic stability. However, mutations in the P53 gene are found in over 50% of ...

Figure 8: Regulation of ALDH3A1 and NECTIN4 by p53. Researchers Jessica J. Miciak, Lucy Petrova, Rhythm Sajwan, Aditya Pandya, Mikayla Deckard, Andrew J. Munoz, and Fred Bunz from the Sidney Kimmel ...

Since its discovery by Arnold Levine in 1979, the tumor protein p53 has transformed the field of cancer research. p53 signaling plays a key role in regulating the cell cycle, maintaining genome ...

In the 1970s, scientists knew that some viruses and chemicals caused cancer, but they didn’t know how. Arnold Levine, a biologist currently at the Institute for Advanced Study researched DNA viruses ...

Researchers have discovered that aneuploidy drives gain-of-function phenotypes in cells expressing mutant p53. Their report has implications for developing therapies targeting mutant p53. The tumor ...

Kovina Therapeutics Inc. today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of ...